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Objectives. This study was designed to test the efficacy and
safety of a fibrin-film–covered stent compared with that of a bare
metal stent in the porcine coronary injury model.
Background. Biodegradable stents are a potential method of
achieving total lesion coverage and delivering local, lesion-specific
drug therapy.
Methods. Two coronary arteries in each pig were randomly
assigned to deployment of either a fibrin-film or a bare tantalum
wire-coil stent. An oversized balloon injury, 1.15 to 1.30 times the
reference vessel diameter, was induced in each coronary segment
before stenting to simulate angioplasty injury. Thirty pigs were
studied: group 1 for 28 days (15 pigs); group 2 for 90 days (5 pigs);
group 3 for 6 months (5 pigs); group 4 for 1 year (5 pigs).
Results. Two pigs died of occlusion of the bare stent and one of
occlusion of the fibrin stent (p > 0.99). There were no significant
differences between the fibrin-stented and bare-stented coronary
segments with regard to arterial injury. In group 1 (28 days, 14
pigs), the mean neointimal thicknesses in the fibrin-stented and
bare-stented groups were 0.57 6 0.31 and 0.57 6 0.27 mm,
respectively (p 5 0.89). In groups 2 to 4 (90 days, four pigs; 6
months, four pigs; 1 year, five pigs), the mean neointimal thick-
nesses for fibrin- and bare-stented coronary segments at the times
studied were 0.48 6 0.26 versus 0.50 6 0.22 mm at 90 days; 0.35 6
0.04 versus 0.35 6 0.16 mm at 6 months; and 0.33 6 0.14 versus
0.30 6 0.14 mm at 1 year (p 5 0.98).
Conclusions. Fibrin-film stents appear to be an excellent can-
didate for local drug delivery because they can completely and
safely cover the stented coronary segment while degrading slowly
over 1 to 3 months. This result is important when compared with
the poor results of previous studies of synthetic polymer stents.
(J Am Coll Cardiol 1998;31:1434–8)
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Intracoronary stents have been shown (1,2) to reduce the
incidence of restenosis compared with balloon angioplasty in
randomized trials of specific patient groups. The reduction in
restenosis achieved with these devices results from greater
initial lumen gain, prevention of elastic recoil and attenuation
of the arterial remodeling process (3,4). Metal stents by
themselves do not inhibit the neointimal response to coronary
injury but actually stimulate this process, with histologic stud-
ies in pigs (5,6) and intravascular ultrasound evaluation in
patients (7,8) identifying neointimal hyperplasia as the cause of
in-stent restenosis.
Studies using a porcine coronary restenosis model indicate
that the structural integrity of the internal elastic lamina is
essential to minimize neointimal thickening (5). Exposure of
arterial components deep to an injured internal elastic lamina
to the blood initiates the first, thrombotic phase of the
restenosis process (9,10). A stent capable of covering an entire
lesion area uniformly might thus attenuate the neointimal
response to vessel injury and reduce the severity of neointimal
hyperplasia.
Biodegradable stents are an alternative method of main-
taining patency during the restenosis period while achieving
total lesion coverage. There is also the potential to deliver
local, lesion-specific therapy. A recent multicenter animal
study using five biodegradable and three nonbiodegradable
polymers incorporated in wire-coil stents, in a porcine model
without previous coronary injury, demonstrated a universal
marked inflammatory response with neointimal thickening
(11). Using the same model, initial results with fibrin-coated
stents were more encouraging (12).
The present study was designed to test the efficacy and
safety of the fibrin-film stent compared with bare metal
stenting, up to 1 year after deployment, in a porcine coronary
injury model. The findings may be of considerable interest
because the fibrin-film stent can provide complete endoluminal
paving by covering 100% of the arterial surface, compared with
the partial coverage achieved with the metal stent alone.
Methods
Animals. The study was performed with the approval of
the Animal Care and Use Committee of the Mayo Clinic. The
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juvenile domestic, crossbred porcine coronary injury model has
been described previously (9). The day before the procedure,
pigs were premedicated with aspirin (650 mg), verapamil
(120 mg) and ticlopidine (250 mg) orally. Before anesthesia,
additional aspirin (325 mg) and ticlopidine (250 mg) were
given to each pig. General anesthesia was achieved with
intramuscular, followed by intravenous, ketamine (30 mg/kg
body weight) and xylazine (3 mg/kg). Additional medication at
the time of induction included atropine (1 mg) and flocillin
(1 g) intramuscularly. During the stenting procedure, an
intraarterial bolus of 10,000 U of heparin was administered.
Oral aspirin, 325 mg/day, was continued for the duration of the
study. Arterial access was obtained by cutdown on the right
external carotid and placement of an 8F sheath. After the
procedure, the animals were continued on a normal diet for
the remainder of their course.
Stent placement. Two coronary arteries in each pig were
randomly assigned to deployment of one fibrin-coated or one
bare tantalum wire-coil Wiktor stent. An oversized balloon
injury, 1.15 to 1.30 times the reference vessel diameter (based
on arterial and nominal balloon sizes), was used in each
coronary segment before stenting to simulate angioplasty
injury. Segments with major side-branches were deliberately
avoided. Both bare and fibrin stents were 15 mm long, hand-
crimped on 20-mm balloons and delivered using standard
guide catheters and wires. Stents were sized to 1.1 to 1.2 times
the reference vessel diameter and the pressure used was
uniformly 6 atm for all deployments.
The preparation of the fibrin stents has been previously
described (12). Briefly, a fibrin film was prepared from porcine
fibrinogen. The fibrinogen was polymerized with porcine
thrombin, compressed, dehydrated and gamma sterilized. Just
before implantation, the stents were rehydrated for 10 min in
20 to 30 ml of heparin at a concentration of 10,000 U/ml (Fig.
1). Thus, after rehydration and before crimping, there were
200 to 300 U of heparin in the fibrin-film stent. The crimping
process is thought to remove roughly half of this amount of
heparin, with the remaining heparin washed away by coronary
blood flow after deployment.
Morphometric analysis. The pigs were euthanized using a
commercial intravenous solution (Sleepaway, 10 ml, Fort
Dodge Laboratories). The hearts were then immediately re-
moved and the coronary arteries fixed by pressure perfusion
(100 mm Hg) with 10% neutral buffered formalin for 24 h.
After fixation, the stented coronary segments were dissected
free and cut at 2-mm perpendicular intervals. The tissues were
subsequently embedded and stained with hematoxylin-eosin
and elastic-van Gieson. Vessel injury severity and neointimal
response were measured by calibrated digital microscopy as
previously detailed (13). Vessel injury at each stent wire site
was scored as follows: 0 5 endothelium denuded; 1 5 internal
elastic lamina lacerated; 2 5 media lacerated; 3 5 external
elastic lamina lacerated. The neointimal thickness was also
measured at each wire site, and mean injury scores and
neointimal responses were calculated for each stented coro-
nary segment.
Study end points. The end points of the study were to
define the efficacy measured by neointimal thickening and the
safety of the fibrin-film stent implant compared with that of the
bare metal stent. Death was defined as procedure related if it
occurred within 24 h of stent deployment. Efficacy was deter-
mined by comparing the morphometric analysis of fibrin-
stented and bare-stented coronary segments at 28 days (group
1), 90 days (group 2), 6 months (group 3) and 1 year (group 4).
Statistical analysis. A sample size of 14 arterial segments
in each group was required to detect a 25% reduction in
neointimal thickness at 28 days, by defining a significance level
of 95% (alpha 0.05) and a statistical power of 80% (beta 0.20).
Two coronary arteries were treated in each pig; thus, a total of
14 animals were used for 28-day (group 1) analysis. Twelve
animals were randomly chosen for extended survival (90 days,
6 months, 1 year) to observe the neointimal response after
fibrin-film, compared with bare metal stenting, over these time
points (n 5 4/group). Thus, allowing for a procedural mortality
of 10%, a total of 30 pigs underwent deployment of one
fibrin-film and one bare metal stent. Statistics used included
the Fisher exact test and two-way analysis of variance.
Results
Sixty stents (one fibrin-film and one bare stent in each pig)
were deployed in 30 pigs. The left anterior descending, circum-
flex and right coronary arteries were each used 10 times for
fibrin-film and bare stent deployment. Angiography immedi-
ately after the stent procedure demonstrated Thrombolysis in
Myocardial Infarction trial (TIMI) grade 3 flow, with no
evidence of fibrin sleeve dislodgment, in all cases. A
procedure-related death occurred in three animals (10%) that
on post mortem was confirmed to be secondary to thrombotic
stent occlusion. Two pigs died of occlusion of the bare stent
and one of occlusion of the fibrin stent. Therefore, the stent
occlusion rates were 6.7% (2 of 30) and 3.3% (1 of 30) for the
bare stent and fibrin stent groups, respectively (p . 0.99). The
number of animals in each group surviving to euthansia was 14
in group 1 (28 days); 4 in group 2 (90 days); 4 in group 3 (6
months); and 5 in group 4 (1 year).
Figure 1. Rehydrated fibrin-film stent.
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Group 1. Fourteen pigs were euthanized at 28 days. There
were no significant differences between the fibrin-stented (n 5
14) and bare-stented (n 5 14) coronary segments with regard
to arterial injury or neointimal response; the mean neointimal
thicknesses in the fibrin- and bare-stented groups were 0.57 6
0.31 and 0.57 6 0.27 mm, respectively (p 5 0.89). The fibrin
stent thus exhibited no more neointimal thickening than the
bare stent (Fig. 2) despite achieving complete arterial injury
site coverage. This result is reflected by the similar injury-
response regression lines for fibrin-film and bare metal stented
coronary segments (Fig. 3).
Groups 2 to 4. Four, four and five pigs survived to 90 days,
6 months and 1 year, respectively. The mean injury scores and
mean neointimal thicknesses for each of these groups are
shown in Table 1. The mean neointimal thicknesses for fibrin-
and bare-stented coronary segments at the times studied were
0.48 6 0.26 versus 0.50 6 0.22 mm, 90 days; 0.35 6 0.04 versus
0.35 6 0.16 mm, 6 months; and 0.33 6 0.14 versus 0.30 6
0.14 mm, 1 year. There were no significant differences between
the neointimal responses in the fibrin stent and bare stent
groups at any of the time points studied (p 5 0.98). However,
neointimal thickness in both groups decreased over time, from
28 days to 1 year.
At 28 days there were only small amounts of exogenous
fibrin present, and none was visible at or after 90 days. The
arterial segments covered by the fibrin-film stent exhibited no
significant foreign body, giant cell or inflammatory reaction up
to 1 year after deployment (Fig. 4). The observed neointimal
hyperplasia appeared to advance through the gradually de-
grading fibrin-film.
Discussion
The present study confirms the safety of the fibrin-film stent
compared with that of a bare metal stent in a porcine coronary
injury model. The fibrin stent thrombosis rate was low (3.3%),
given that the animals sustained a significant arterial injury
before stenting, and that the pigs received only a single bolus
of heparin and no postprocedural ticlopidine. It is possible that
rehydrating the fibrin-film stent in a heparinized solution
contributed to this low thrombosis rate. The short to midterm
data demonstrate no significant neointimal obstruction or late
mortality up to 1 year after stenting.
The fibrin-film stent did not inhibit neointimal thickening
compared with that for the bare metal stent. The adventitia
seems to play an integral role in neointimal response to injury,
Figure 2. Group 1: representative low magnification sections prepared
for morphometric analysis showing a fibrin-film stent with residual
fibrin present (top) and a bare metal stent (bottom) 28 days after
deployment.
Figure 3. Group 1: injury-response regression analysis for fibrin-film–
and bare metal–stented coronary segments.
Table 1. Groups 2 to 4: Mean (6SD) Neointimal Thickness by
Mean Injury Score
Stent
Injury
(mm)
Neointima
(mm)
Group 2 (n 5 4; 90 days)
Bare 1.7 6 0.6 0.50 6 0.22
Fibrin 1.0 6 0.9 0.48 6 0.26
Group 3 (n 5 4; 6 mo)
Bare 2.3 6 0.6 0.35 6 0.16
Fibrin 2.5 6 0.2 0.35 6 0.04
Group 4 (n 5 5; 1 yr)
Bare 2.1 6 0.3 0.30 6 0.14
Fibrin 2.1 6 0.3 0.33 6 0.14
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which may partly explain the lack of attenuation observed after
fibrin-film stenting (13–15). However, this result in itself is
important when compared with results of previous synthetic
polymer stent studies. In contrast to those studies, the
fibrin-film stent did not stimulate neointimal thickening de-
spite achieving total arterial coverage at the treatment site.
Polymer stents. To be clinically applicable, a polymeric
stent needs to incorporate sufficient mechanical support to
maintain lumen gain and vessel patency. The device should
allow endothelialization of the diseased arterial segment after
the procedure. In addition, the stent should be biocompatible
and should not initiate local thrombus formation or foreign
body reaction. Such stents could also act as a vehicle for local
drug delivery during the period associated with neointimal
thickening.
The porcine model of coronary restenosis, compared with
other models in common in use, more closely reflects the
process observed in human atherectomy and autopsy speci-
mens (16). Initial results with polymeric stenting using the
porcine model were disappointing. A polyethylene terephtha-
late meshwork stent caused an extensive inflammatory, prolif-
erative response with coronary occlusion in all stented seg-
ments (17). In a recent multicenter animal study (11), five
biodegradable and three nonbiodegradable polymers incorpo-
rated in wire-coil stents were implanted in the porcine coro-
nary model. Five to 10 stents were placed in four to six animals
in each of the eight polymer groups. The arterial patency rate
at 4 weeks ranged from 70% to 100%. Five polymer groups
demonstrated an eccentric coronary lumen reduction angio-
graphically at the site of the stent implant. All eight polymers
evoked a marked vessel wall inflammatory reaction. This
powerful induction of neointimal proliferation by polymeric
stenting would have to be controlled before their potential
could be investigated in humans.
Fibrin-film stents. Fibrin has been found to have many
promising applications within the medical field, such as en-
hancing the endothelialization of peripheral vascular grafts in
vitro (18) and promoting operative hemostasis during cardio-
vascular surgery (19–21). Studies in the porcine coronary
model indicate that native fibrin is deposited at the site of
arterial injury and, in part, determines the neointimal response
(5,10). This evidence prompted the first study assessing the
response of the arterial wall to fibrin-coated stents (12).
Using the same porcine coronary model, 34 such stents
were placed in 20 animals with no acute complications.
Follow-up angiography at 28 days confirmed patency in all 31
remaining stented coronary segments. In all cases the fibrin
was still structurally intact and completely endothelialized.
Importantly, there was no exaggerated neointimal response or
foreign body reaction to the fibrin stent, and local vascular
integrity was maintained.
The use of autologous vein grafts to achieve total natural
stent coverage has been reported with encouraging initial
results. In the porcine model, 27 autologous vein graft stents
were deployed in iliac arteries, with uncoated stents acting as
control stents (22). Follow-up ranged from 7 days to 6 months.
All autologous vein graft stents remained patent and became
incorporated into the arterial wall after 2 months. Also, no
exaggerated neointimal response was observed. The same
group has deployed these stents in seven patients without
complications for a mean follow-up period of up to 4 months
(23).
The present study indicates that the fibrin stent alone does
not attenuate the neointimal response to coronary injury
compared with that for a bare metal stent. However, fibrin
appears to be an ideal candidate for local drug delivery
because it can completely and safely cover the stented coro-
nary segment while degrading slowly for 1 to 3 months. This
attribute is in contrast to bare metal stents, which cover less
than one-third of the lesion surface area on deployment (24)
and are thus limited in their ability to deliver site-specific
therapy. However, total arterial coverage does make the
avoidance of major coronary side-branches a practical concern.
The rate at which fibrin is reabsorbed depends on its
formulation. It should therefore be feasible to control the rate
of biodegradation by varying the formulation. In the same way,
one may vary the matrix size and incorporate microcapsules
capable of local drug delivery (25). This approach would add to
the potential of the fibrin stent to inhibit the neointimal
response that was still observed with the stand-alone device.
Commercially available fibrin products were banned by the
Food and Drug Administration in 1978 because of concerns
about viral transmission (26). The fibrin-film incorporated in
the present stent is dehydrated and gamma sterilized before
use, thus removing any potential infectious risk. In addition,
the fibrinogen used comes from human donors screened for
infectious viruses. Alternative sources of fibrin include autol-
ogous donation in nonemergent cases (21) and, potentially,
transgenic animals or recombinant DNA technology.
Conclusions. In the present porcine model, fibrin acted as
an excellent biocompatible and biodegradable polymeric coat-
ing when incorporated into metal stents. As such, it has clinical
potential as part of a “hybrid stent,” composed of a mechanical
metal scaffolding with a coating incorporating local drug
Figure 4. Group 4: representative low magnification section prepared
for morphometric analysis showing a fibrin-film stent 1 year after
deployment.
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delivery, to achieve complete endoluminal paving and deliver
antithrombogenic or antiproliferative therapy, or both, uni-
formly across the arterial injury site. We are presently assessing
the capability of the fibrin-film stent to deliver antiproliferative
gene and radiation therapy in the porcine restenosis model.
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